In reply
Karen J. Kluin(University of Michigan), Jewel Johanns(Johnson & Johnson (United States)), Leslie A. Bruch(University of Michigan), Norman L. Foster(University of Utah), Anders A. F. Sima(Wayne State University), Sid Gilman(University of Michigan), Constance J. D’Amato(University of Michigan), Roderick J. A. Little(University of Michigan), Laurie Bluemlein(University of Michigan)
Cited by 0
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Redefine statistical significance
|Nature Human Behaviour|2017|2.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2019|1.2k
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
|New England Journal of Medicine|2012|1.1k